SCHEMBL6018784

SCHEMBL6018784

CCOC(=O)c1cc(-c2ccccc2)c(C)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.52
HPGD P15428 7/20 0.52
KDM4E B2RXH2 6/20 0.52
TDP1 Q9NUW8 3/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
MAPT P10636 6/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
HSD17B10 Q99714 3/20 0.51
GAA P10253 3/20 0.51
NPC1 O15118 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK14 Q16539 1/20 0.50
MAPK1 P28482 1/20 0.48
GRM6 O15303 3/20 0.48
CDC7 O00311 1/20 0.48
TRPM8 Q7Z2W7 1/20 0.48
DBF4 Q9UBU7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018669 0.87 MAPK14 (0.65) ALDH1A1HPGDKDM4ETDP1L3MBTL1
SCHEMBL14234474 0.85 ALDH1A1 (0.59) ALDH1A1HPGDKDM4ETDP1L3MBTL1
SCHEMBL1029314 0.82 PLK1 (0.62) ALDH1A1HPGDKDM4ETDP1L3MBTL1
SCHEMBL1797326 0.80 KDM4E (0.55) ALDH1A1HPGDKDM4EMAPTRAB9A
SCHEMBL1801707 0.79 PLK1 (0.43) ALDH1A1HPGDKDM4EMAPTSMN1; SMN2
SCHEMBL13088494 0.79 HPGD (0.60) ALDH1A1HPGDKDM4ETDP1L3MBTL1
SCHEMBL6454412 0.78 MAPK1 (0.52) MAPK1
SCHEMBL9825151 0.77 ALDH1A1 (0.51) ALDH1A1HPGDKDM4ETDP1L3MBTL1
SCHEMBL5033848 0.76 IL2 (0.46) ALDH1A1KDM4EMAPTRAB9ASMN1; SMN2
SCHEMBL4830396 0.76 TSHR (0.63) ALDH1A1HPGDKDM4ETDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US claimed
EP-1854804-B1 Heterocyclic metallocene compounds and use thereof in catalyst systems for producing olefin polymers BASELL POLYOLEFINE GMBH (DE) 2011-05-04 EP disclosed
EP-1412347-B1 PROCESS FOR THE PREPARATION OF HETEROCYCLIC PENTALENE DERIVATIVES BASELL POLYOLEFINE GMBH (DE) 2006-01-11 EP disclosed
US-6930190-B2 Process for the preparation of heterocyclic pentalene derivatives BASELL POLYOLEFINE GMBH (DE) 2005-08-16 US disclosed
US-20040192931-A1 Process for the preparation of heterocyclic pentalene derivatives EQUISTAR CHEMICALS, LP 2004-09-30 US disclosed
EP-1412347-A1 PROCESS FOR THE PREPARATION OF HETEROCYCLIC PENTALENE DERIVATIVES Basell Polyolefine GmbH (DE) 2004-04-28 EP disclosed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US disclosed
WO-2003014107-A1 PROCESS FOR THE PREPARATION OF HETEROCYCLIC PENTALENE DERIVATIVES BASELL POLYOLEFINE GMBH (DE) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192931-A1 Process for the preparation of heterocyclic pentalene derivatives CBR3, CBR1, ADH5 ALDH1A1 805/4885HPGD 330/4885KDM4E 3121/4885
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them MMP11, MMP13, CBR1 ALDH1A1 563/4885HPGD 612/4885KDM4E 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.